Information  X 
Enter a valid email address

Hikma Pharmaceutical (HIK)

  Print      Mail a friend       Annual reports

Friday 18 May, 2018

Hikma Pharmaceutical

AGM Results

RNS Number : 6033O
Hikma Pharmaceuticals Plc
18 May 2018
 

 

Hikma Pharmaceuticals PLC

Voting Results of 2018 Annual General Meeting

LONDON, 18 May 2018 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 18 May 2018 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 17 were passed as ordinary resolutions and Resolutions 18 to 21 were passed as special resolutions.

As previously announced, Dr. Ronald Goode retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 28 March 2018) is set out below. The number of Ordinary Shares in issue on 18 May 2018 was 240,940,604.

Resolution

Votes For

%

Votes Against

%

Total Cast

Withheld

1. To receive the 2017 report and accounts

196,394,230

99.96

72,200

0.04

196,466,430

245,708

2. To approve a final dividend of 23 cents per share

196,485,553

99.89

225,796

0.11

196,711,349

788

3. To re-appoint PricewaterhouseCoopers LLP as auditors

196,099,742

99.69

610,679

0.31

196,710,421

1,717

4.To authorise the Audit Committee to determine the auditors' remuneration

196,703,625

100.00

5,721

0.00

196,709,346

2,792

5. To elect Siggi Olafsson as a director

195,815,999

99.55

894,642

0.45

196,710,641

1,497

6. To re-elect Said Darwazah as a director

190,417,700

96.80

6,298,814

3.20

196,716,514

1,622

7. To re-elect Mazen Darwazah as a director

193,925,828

98.58

2,783,900

1.42

196,709,728

2,410

8. To re-elect Robert Pickering as a director

190,879,517

98.02

3,848,509

1.98

194,728,026

1,984,111

9.To re-elect Ali Al-Husry as a director

195,245,623

99.26

1,464,293

0.74

196,709,916

2,222

10. To re-elect Patrick Butler as a director

193,317,043

98.28

3,393,072

1.72

196,710,115

2,022

11. To re-elect Dr. Jochen Gann as a director

195,107,616

99.19

1,602,499

0.81

196,710,115

2,022

12. To re-elect John Castellani as a director

193,529,031

98.38

3,180,885

1.62

196,709,916

2,222

13. To re-elect Dr. Pamela Kirby as a director

190,289,183

96.74

6,421,682

3.26

196,710,865

1,272

14. To re-elect Nina Henderson as a director

192,848,157

98.04

3,862,508

1.96

196,710,665

1,472

15. To approve the remuneration report for the year ended 31 December 2017

169,750,519

86.36

26,815,358

13.64

196,565,877

146,261

16. To approve and adopt the 2018 Management Incentive Plan

195,620,834

99.45

1,088,481

0.55

196,709,315

2,822

17. Authority to allot shares

166,598,638

84.69

30,112,333

15.31

196,710,971

1,167

18. To dis-apply pre-emption rights for general purposes

196,660,802

99.97

50,469

0.03

196,711,271

867

19. To dis-apply pre-emption rights for an acquisition or other capital investment

195,530,359

99.40

1,179,711

0.60

196,710,070

2,067

20. To authorise the Company to purchase its own shares

195,989,881

99.68

621,703

0.32

196,611,584

100,553

21. To authorise the Company to hold general meetings on no less than 14 clear days' notice

187,831,722

95.49

8,878,028

4.51

196,709,750

2,388

 

Declaration of final dividend

The dividend of 23 cents per share will be paid on 24 May 2018 to shareholders on the register on 6 April 2018.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.3521 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

VP for Investor Relations and Strategy

 

+44 20 7399 2670

 

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.  For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

 

 

LEI: 549300BNS685UXH4JI75


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGUWRURWRAVAAR

a d v e r t i s e m e n t